RhumbLine Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.01M | Buy |
404,743
+41,241
| +11% | +$565K | 0.01% | 1288 |
|
|
2026
Q1 | $4.52M | Buy |
363,502
+162,752
| +81% | +$2.19M | ﹤0.01% | 1448 |
|
|
2025
Q4 | $2.53M | Sell |
200,750
-31,357
| -14% | -$359K | ﹤0.01% | 1735 |
|
|
2025
Q3 | $2.32M | Sell |
232,107
-5,623
| -2% | -$50.5K | ﹤0.01% | 1828 |
|
|
2025
Q2 | $1.92M | Sell |
237,730
-183
| -0.1% | -$1.38K | ﹤0.01% | 1907 |
|
|
2025
Q1 | $1.99M | Buy |
237,913
+5,649
| +2% | +$47.2K | ﹤0.01% | 1812 |
|
|
2024
Q4 | $1.84M | Buy |
232,264
+7,875
| +4% | +$66.1K | ﹤0.01% | 1927 |
|
|
2024
Q3 | $1.87M | Sell |
224,389
-8,828
| -4% | -$69K | ﹤0.01% | 1948 |
|
|
2024
Q2 | $1.48M | Buy |
233,217
+30,286
| +15% | +$192K | ﹤0.01% | 2040 |
|
|
2024
Q1 | $1.23M | Sell |
202,931
-9,860
| -5% | -$55.6K | ﹤0.01% | 2136 |
|
|
2023
Q4 | $1.29M | Buy |
212,791
+13,386
| +7% | +$59.6K | ﹤0.01% | 2135 |
|
|
2023
Q3 | $841K | Buy |
199,405
+623
| +0.3% | +$2.32K | ﹤0.01% | 2300 |
|
|
2023
Q2 | $616K | Buy |
198,782
+36,597
| +23% | +$78K | ﹤0.01% | 2558 |
|
|
2023
Q1 | $225K | Buy |
162,185
+1,672
| +1% | +$3.33K | ﹤0.01% | 2710 |
|
|
2022
Q4 | $319K | Buy |
160,513
+4,862
| +3% | +$10.9K | ﹤0.01% | 2655 |
|
|
2022
Q3 | $314K | Buy |
155,651
+8,930
| +6% | +$25K | ﹤0.01% | 2708 |
|
|
2022
Q2 | $467K | Buy |
146,721
+2,139
| +1% | +$7.75K | ﹤0.01% | 2531 |
|
|
2022
Q1 | $603K | Sell |
144,582
-13,640
| -9% | -$60.4K | ﹤0.01% | 2340 |
|
|
2021
Q4 | $758K | Buy |
158,222
+5,688
| +4% | +$28.4K | ﹤0.01% | 2328 |
|
|
2021
Q3 | $815K | Buy |
152,534
+2,938
| +2% | +$14.8K | ﹤0.01% | 2327 |
|
|
2021
Q2 | $766K | Sell |
149,596
-4,654
| -3% | -$26.5K | ﹤0.01% | 2363 |
|
|
2021
Q1 | $1.04M | Sell |
154,250
-6,793
| -4% | -$37.6K | ﹤0.01% | 2177 |
|
|
2020
Q4 | $736K | Buy |
161,043
+7,290
| +5% | +$32.3K | ﹤0.01% | 2273 |
|
|
2020
Q3 | $597K | Sell |
153,753
-23,490
| -13% | -$100K | ﹤0.01% | 2202 |
|
|
2020
Q2 | $844K | Buy |
177,243
+22,237
| +14% | +$91.6K | ﹤0.01% | 2116 |
|
|
2020
Q1 | $539K | Buy |
155,006
+7,987
| +5% | +$33.8K | ﹤0.01% | 2132 |
|
|
2019
Q4 | $709K | Buy |
147,019
+16,872
| +13% | +$58.6K | ﹤0.01% | 2225 |
|
|
2019
Q3 | $377K | Sell |
130,147
-745
| -0.6% | -$2.6K | ﹤0.01% | 2450 |
|
|
2019
Q2 | $938K | Buy |
130,892
+7,042
| +6% | +$72K | ﹤0.01% | 2086 |
|
|
2019
Q1 | $1.75M | Sell |
123,850
-1,460
| -1% | -$19.3K | ﹤0.01% | 1788 |
|
|
2018
Q4 | $1.7M | Buy |
125,310
+37,713
| +43% | +$680K | ﹤0.01% | 1747 |
|
|
2018
Q3 | $1.94M | Sell |
87,597
-5,685
| -6% | -$120K | ﹤0.01% | 1676 |
|
|
2018
Q2 | $1.53M | Buy |
+93,282
| New | +$1.64M | ﹤0.01% | 1815 |
|
Other funds holding AMRX
TGA
RCMNY
RhumbLine Advisers's AMRX Position: Q2 2026 in Review
RhumbLine Advisers increased its Amneal Pharmaceuticals (AMRX) stake by 11% in Q2 2026, buying an estimated $565K and bringing the position to 404,743 shares worth $7.01M. The position accounts for 0.01% of the portfolio, ranked #1288.
RhumbLine Advisers first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- RhumbLine Advisers held 404,743 shares of Amneal Pharmaceuticals worth $7.01M as of Q2 2026.
- RhumbLine Advisers bought 41,241 Amneal Pharmaceuticals shares in Q2 2026, an estimated $565K.
- Amneal Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1288 holding.
- RhumbLine Advisers first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.